{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["97(5)"],"submitter":["Wilson WH"],"pubmed_abstract":["<h4>Background</h4>A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting.<h4>Design and methods</h4>The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years of age and at least stage II. Radiaton therapy was not permitted on study. Median age was 58 years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk. Immunohistochemical biomarkers for cell of origin and proliferation were performed.<h4>Results</h4>With a m"],"journal":["Haematologica"],"pagination":["758-65"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3342980"],"repository":["biostudies-literature"],"pubmed_title":["A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype."],"pmcid":["PMC3342980"],"pubmed_authors":["Jung SH","Hsi ED","Hurd D","Johnson J","Porcu P","Dunleavy K","Martin SE","Canellos G","Jones D","Cancer Leukemia Group B","Wilson WH","Cheson BD","Zelenetz AD","Czuczman M","Said J","Lai R","Chadburn A"],"additional_accession":[]},"is_claimable":false,"name":"A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.","description":"<h4>Background</h4>A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting.<h4>Design and methods</h4>The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years of age and at least stage II. Radiaton therapy was not permitted on study. Median age was 58 years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk. Immunohistochemical biomarkers for cell of origin and proliferation were performed.<h4>Results</h4>With a m","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 May","modification":"2025-04-18T14:48:21.052Z","creation":"2019-03-27T00:52:57Z"},"accession":"S-EPMC3342980","cross_references":{"pubmed":["22133772"],"doi":["10.3324/haematol.2011.056531"]}}